Acute Parkinson's Crisis (Parkinsonism-Hyperpyrexia Syndrome)

1. Clinical Overview

Summary

Acute Parkinson’s Crisis, also known as Parkinsonism-Hyperpyrexia Syndrome (PHS), Akinetic Crisis, or Malignant Syndrome in Parkinson's Disease, is a rare but life-threatening neurological emergency. It primarily affects patients with Parkinson’s Disease (PD) or other parkinsonian syndromes (like Multiple System Atrophy or Dementia with Lewy Bodies). The hallmark of the condition is a sudden, massive worsening of motor symptoms—characterized by "lead-pipe" rigidity and total akinesia—alongside systemic features including high fever (hyperpyrexia), altered mental status, and autonomic instability.

Pathophysiologically, PHS represents a catastrophic failure of the brain's dopaminergic system, typically triggered by the abrupt withdrawal or reduction of dopaminergic medications (like Levodopa, dopamine agonists, or amantadine) or by acute physiological stressors such as infection, surgery, or dehydration. It is clinico-pathologically identical to Neuroleptic Malignant Syndrome (NMS), which is caused by dopamine antagonists; however, PHS is caused by a deficiency of dopamine agonists.

Early recognition is paramount, as the syndrome carries a high mortality rate (up to 20%) due to complications like rhabdomyolysis-induced acute kidney injury (AKI), respiratory failure, and disseminated intravascular coagulation (DIC). Management focuses on immediate restoration of dopaminergic activity, aggressive supportive care in an intensive care setting, and treating underlying precipitants.

Key Facts

• Classic Triad: Severe rigidity, hyperthermia, and altered consciousness.
• Precipitant: 80% of cases are triggered by medication changes or systemic infection.
• Laboratory Feature: Serum Creatine Kinase (CK) elevation is the most sensitive marker of muscle involvement and rhabdomyolysis risk.
• Mortality: 4-20%, significantly reduced by prompt dopamine replacement.
• Key Differential: Neuroleptic Malignant Syndrome (must ask about haloperidol/metoclopramide use).
• First-line treatment: Immediate L-Dopa restoration (via NG tube or patch) and IV hydration.

Clinical Pearls

[!TIP] "The NPO Rule" — Parkinson's patients made NPO for surgery are at extreme risk. Always plan a "Dopamine Bridge" using a rotigotine patch or an NG tube. Never "wait and see" if they can swallow post-operatively.

[!IMPORTANT] "Amantadine Withdrawal" — Amantadine withdrawal is a frequent but often forgotten trigger. Its effects on NMDA receptors mean its withdrawal leads to a glutamate storm that exacerbates parkinsonian rigidity.

[!WARNING] "The Prochlorperazine Trap" — In a patient with worsening Parkinson's and nausea, never give D2 antagonists like prochlorperazine or metoclopramide. This can turn a mild motor "off" into a fatal akinetic crisis. Use ondansetron.

Why This Matters Clinically

PHS is a high-stakes diagnosis for neurologists, emergency physicians, and intensivists. It is one of the few neurological conditions where minutes matter—early administration of dopamine can literally stop the progression to multi-organ failure. In an aging society where Parkinson's prevalence is rising, hospitalists must be vigilant, especially when PD patients are admitted for non-neurological reasons (like hip fractures), as their Parkinson's medications are frequently mismanaged.

---

2. Epidemiology

Incidence & Prevalence

PHS is considered rare, affecting approximately 0.3% to 0.9% of the Parkinson's population annually [1, 3, 7]. However, this figure likely underrepresents the incidence in hospitalized PD patients, where the stress of acute illness and disruption of medication schedules are concentrated.

Demographics

• Age: Primarily older adults, following the age-prevalence curve of Parkinson's Disease.
• Disease Stage: More common in advanced PD (Hoehn and Yahr stage III-IV). These patients have minimal dopamine storage capacity in the striatum and are more "brittle" to medication changes.
• Cognitive Status: Patients with pre-existing dementia (e.g., PDD or DLB) may be at higher risk due to more widespread neurodegeneration in autonomic and thermoregulatory centers.

Risk Factors

1. Advanced Parkinson's Disease: Longer disease duration increases vulnerability.
2. Prior Crisis: History of a previous akinetic episode.
3. Polypharmacy: Complex medication regimens where stopping one agent can disrupt the balance of others.
4. Cognitive Impairment: Inability of the patient to advocate for their medication timing.

Common Precipitants

In the majority of cases, a specific trigger can be identified through careful history.

---

3. Aetiology & Pathophysiology

Aetiology

The central cause is a sudden, severe depletion of central dopaminergic activity. This is most commonly "exogenous" (medication stopped) but can be "endogenous" (increased metabolic demand during sepsis depletes the already low dopamine reserves).

Medications with High Withdrawal Risk:

1. Levodopa: The "gold standard" therapy; withdrawal is the most frequent trigger.
2. Dopamine Agonists: Rotigotine, Ropinirole, Pramipexole, Apomorphine.
3. Amantadine: Withdrawal leads to NMDA-receptor overactivity, causing severe rigidity.
4. COMT Inhibitors: Entacapone, Tolcapone, Opicapone.

Pathophysiology: The Molecular Crisis

1. Basal Ganglia Failure: The Motor Crisis

The core of PHS is the "freezing" of the motor system. In PD, the substantia nigra pars compacta (SNpc) has lost its dopaminergic neurons. The striatum depends on a steady supply of exogenous Levodopa.

• Loss of D1 Stimulation (Direct Pathway): Reduces motor initiation by the striatum sending less inhibition to the GPi.
• Loss of D2 Inhibition (Indirect Pathway): Causes overactivity of the globus pallidus internus (GPi) and subthalamic nucleus (STN).
• The "Thalamic Gate": The overactive GPi sends massive GABAergic (inhibitory) signals to the Ventrolateral Thalamus.
• Result: The "Gate" to the motor cortex is slammed shut, leading to "lead-pipe" rigidity and total akinesia.

2. Hypothalamic Failure: The Thermal Crisis

The hypothalamus is the body's thermostat, and dopamine is a critical neurotransmitter in its thermoregulatory pathways (specifically the preoptic area).

• Central Dysregulation: Dopamine depletion shifts the hypothalamic set-point upward, causing the body to treat a normal temperature as "hypothermic" and stimulating heat production.
• Peripheral Heat Production: The unrelenting lead-pipe muscle rigidity generates massive amounts of metabolic heat through continuous muscle fiber contraction.
• Result: Malignant hyperpyrexia (often > 40°C).

3. Autonomic Dysregulation

Dopamine pathways in the brainstem (including the nucleus tractus solitarius) modulate autonomic tone.

• Depletion leads to sympathetic overactivity and a failure of compensatory baroreflexes.
• Result: Tachycardia, labile blood pressure, and profuse diaphoresis.

4. The Rhabdomyolysis Cascade

Severe, sustained muscle contraction (rigidity) leads to mechanical muscle fiber breakdown and myocyte necrosis.

• Myoglobin Release: Muscle breakdown releases myoglobin into the blood.
• Renal Toxicity: Myoglobin is directly toxic to renal tubular cells and forms obstructive casts in the presence of dehydration and acidic urine.
• Result: Acute Kidney Injury (AKI) and life-threatening hyperkalemia.

4. Detailed Molecular Pathophysiology: The Dopamine-Glutamate Storm

The pathophysiology of Parkinsonism-Hyperpyrexia Syndrome (PHS) is a complex interplay of neurotransmitter depletion and secondary metabolic failure.

A. Dopamine Receptor Subtypes (D1-D5)

In PHS, the sudden loss of stimulation across all dopamine receptor subtypes leads to specific physiological consequences:

• D1-like (D1, D5): These receptors are Gs-coupled and stimulate the direct pathway. Their loss leads to decreased activation of the motor cortex.
• D2-like (D2, D3, D4): These are Gi-coupled. The D2 receptor is the primary regulator of the indirect pathway. Its lack of stimulation leads to massive disinhibition of the Subthalamic Nucleus (STN).
• Hypothalamic D2: Specifically modulates the thermoregulatory neurons. Loss leads to the "set-point" elevation seen in malignant hyperthermia.

B. The "Indirect Pathway" and STN Disinhibition

The Subthalamic Nucleus is the "motor of the basal ganglia." In the absence of dopamine, the STN becomes pathologically hyperactive. It sends massive glutamatergic (excitatory) pulses to the Globus Pallidus Internus (GPi) and Substantia Nigra Reticulata (SNr). This "over-inhibition" of the thalamus is what causes the profound lead-pipe rigidity that distinguishes PHS from other forms of parkinsonism.

C. Thermoregulatory Circuits

The preoptic area of the hypothalamus normally uses dopamine to suppress heat production. In PHS, this brake is removed. This is compounded by:

1. Uncoupling Protein (UCP) activation in brown adipose tissue.
2. Sustained Myocyte Contraction: The lead-pipe rigidity is a continuous isometric contraction of nearly all skeletal muscle groups, generating joules of heat that exceed the body's cooling capacity.

D. Myocyte Necrosis Pathways

Rigidity leads to intracellular calcium overload within the muscle fibers.

• Calpain Activation: High intracellular calcium activates calpains (proteases) that digest the cytoskeleton.
• Mitochondrial Failure: Calcium overload causes mitochondrial permeability transition pore (mPTP) opening, leading to ATP depletion and cell death.
• Myoglobin Release: The resulting sarcolemmal rupture releases myoglobin, CK, and potassium into the systemic circulation.

---

5. Clinical Presentation: Expanded Phenotypes

1. The Classic PHS Phenotype

• Rapid Progression: Symptoms evolve over 12-48 hours.
• Triad: Rigid + Hot + Confused.
• Autonomic Signature: Tachycardia (HR > 130), Profuse sweating (Diaphoresis), and Labile BP.

2. The "Akinetic-Mute" Variant

Some patients do not develop high fevers initially but instead fall into a state of total "frozen" mutism.

• Danger: Often misdiagnosed as "depressive stupor" or "catatonia."
• Key Sign: Profound "waxy flexibility" is absent; instead, true lead-pipe resistance is felt.

3. The "DBS-Failure" Phenotype

Patients with Deep Brain Stimulation who experience sudden battery failure or lead displacement.

• Presentation: Often more explosive than medication withdrawal.
• Clinical Pearl: If a patient has DBS, always check the device status immediately with a programmer or X-ray.

4. The "Sepsis-Mimic"

In the elderly, PHS can present identically to septic shock.

• Distinguishing Feature: The "Rigidity Test." Even in septic delirium, patients rarely exhibit the generalized, constant rigidity of PHS.

---

6. Differential Diagnosis in Depth

---

7. Comprehensive Investigation Protocols

1. Interpreting the CK/Creatinine Ratio

A CK level that is disproportionately high compared to the creatinine elevation suggests early rhabdomyolysis where the kidneys are still compensating. A CK > 20,000 with any rise in creatinine is an indication for aggressive "renal protection" protocols.

2. Acid-Base and Electrolyte Disturbance

• Metabolic Acidosis: Often due to lactate (from muscle exertion) and renal failure.
• Hyperkalemia: The "Killer" in PHS. Levels > 6.0 mmol/L require emergent treatment with calcium gluconate, insulin/dextrose, and potentially RRT.
• Hypocalcemia: Early phase (sequestration in muscle); requires monitoring to avoid over-correction and subsequent hypercalcemia in the recovery phase.

3. CSF Analysis

Lumbar puncture is often performed to rule out meningitis.

• PHS Finding: Typically normal protein and glucose, with less than 5 WBCs.
• Note: A slightly elevated protein may be seen due to blood-brain barrier disruption from hyperthermia.

4. Imaging Protocols

• MRI Brain: Not usually indicated in the acute phase but may show changes in the basal ganglia or cerebellum in severe, prolonged hyperthermia.
• CXR: Mandatory Q24H in the ICU to monitor for ARDS and aspiration pneumonia.

---

Symptoms: The Patient's Story

The onset is typically acute to subacute (over 24-72 hours).

Cardinal Symptoms

• "Total Freeze": Sudden inability to initiate any movement.
• Difficulty Swallowing: Severe dysphagia, leading to drooling and aspiration risk.
• Speech Failure: Profound dysarthria or total mutism.
• Systemic Distress: Feeling extremely hot, confused, and weak.
• Dark Urine: "Tea-colored" or "cola-colored" urine is a sign of significant rhabdomyolysis.

Signs: The Clinical Exam

Neurological Examination

• Lead-Pipe Rigidity: Universal, affecting limbs, trunk, and neck. It does not "give" like spasticity.
• Akinesia: Absolute lack of spontaneous movement.
• Altered Consciousness: Ranges from mild delirium and hallucinations to stupor and coma.
• Reflexes: Usually normal or reduced.

Systemic Signs (The "PHS Signature")

• Hyperthermia: Temperature often exceeds 39.0°C and can reach 41.5°C.
• Tachycardia: Often > 120 bpm and labile.
• Blood Pressure: Fluctuates wildly (autonomic storm).
• Diaphoresis: Profuse, "drenching" sweats.

Red Flags

[!CAUTION] Red Flags for Immediate ICU Transfer:

• Temperature > 40.0°C
• GCS less than 10 (Inability to protect airway)
• Creatine Kinase (CK) > 10,000 U/L
• Oliguria (Suggesting AKI)

---

5. Differential Diagnosis

---

6. Investigations

First-Line (Bedside/Immediate)

1. Serum Creatine Kinase (CK): The most critical test. Levels are often > 10,000 U/L and can exceed 100,000 U/L.
2. ECG: Look for peaked T-waves (hyperkalemia) or signs of ischemia from tachycardia.
3. Urea & Electrolytes: Look for AKI (rising creatinine) and hyperkalemia.
4. Chest X-Ray: Rule out aspiration pneumonia.

Laboratory Tests

• Full Blood Count: Leukocytosis is common due to stress.
• Liver Function Tests: Elevated AST/LDH (leakage from muscle).
• Coagulation Screen: Look for signs of DIC.
• Blood & Urine Cultures: Screen for precipitants.

---

7. Management

Management Algorithm

1. Airway (A): Secure if GCS less than 10 or severe aspiration risk.
2. Breathing (B): Monitor for respiratory failure due to chest wall rigidity.
3. Circulation (C): Aggressive IV Hydration. 3-6 liters of Normal Saline in 24 hours to maintain urine output > 200 mL/hr.
4. Disability (D): Restore Dopamine immediately.

Acute/Emergency Management

1. Immediate Dopamine Replacement (The "Dopamine Bridge")

• Levodopa/Carbidopa: If the patient has an NG tube, give crushed L-Dopa. Increase the dose by 25-50% to break the crisis.
• Rotigotine Patch: Apply 4mg/24h or 8mg/24h patch immediately. This provides continuous stimulation.
• Apomorphine: If the crisis is severe, start a subcutaneous infusion (1-4 mg/hr) [5, 8].

2. Managing Rigidity and Hyperthermia

• Cooling: External cooling blankets, ice packs, cold IV fluids.
• Dantrolene: In refractory cases, give 1-2.5 mg/kg IV every 6 hours [6].
• Bromocriptine: D2 agonist via NG tube (2.5 - 5 mg every 8 hours).

3. Supportive Care in ICU

• Renal Protection: Maintain urine output > 200 mL/hr.
• VTE Prophylaxis: Mandatory LMWH.
• Nutrition: Early enteral feeding.

---

8. Advanced Management Protocols: The Consultant's Guide

1. Apomorphine Titration Protocol

Apomorphine is the most potent rapid-onset dopamine agonist.

• Initial Bolus: 2mg (0.2mL) SC to assess responsiveness and BP stability.
• Maintenance Infusion: Start at 1mg/hr (10mg/hr is the absolute max).
• Monitoring: Check BP every 15 mins for the first hour of infusion. If BP drops > 20 mmHg, reduce rate.
• Cessation: Do not stop abruptly. Taper by 0.5mg/hr every 12 hours once oral/NG L-Dopa is tolerated.

2. Levodopa-Carbidopa Intestinal Gel (LCIG) via Temporary NJ Tube

For patients already on Duodopa, or for "brittle" refractory cases:

• Procedure: Insert a Nasojejunal (NJ) tube under fluoroscopic or endoscopic guidance.
• Initial Rate: Continue their previous pump settings. If they were not on LCIG, start at 2mL/hr and titrate by 0.5mL/hr every 4 hours based on motor rigidity.
• Advantage: Bypasses the stomach (gastroparesis) entirely, which is often the cause of "failure to respond" in PHS.

3. Dantrolene Dosing and Precautions

• Indication: T > 39.5°C or intense lead-pipe rigidity causing metabolic acidosis.
• Dose: 1 - 2.5 mg/kg IV push, then repeat until temperature falls or max dose of 10mg/kg is reached.
• Caution: Hepatotoxicity. Check LFTs daily. Avoid in patients with pre-existing end-stage liver disease unless the crisis is immediately life-threatening.
• Interaction: Do not use calcium-channel blockers with Dantrolene as it may trigger hyperkalemia and cardiovascular collapse.

4. Sedation and Analgesia in PHS

• Benzodiazepines: Midazolam infusion is excellent for reducing muscle tone and anxiety.
• Propofol: Use with extreme caution. There is a theoretical risk of Propofol Infusion Syndrome (PRIS) exacerbating the metabolic acidosis and rhabdomyolysis already present in PHS.
• Dexmedetomidine: An alpha-2 agonist that can help manage tachycardia and hypertension without suppressing respiratory drive as much as opioids.

---

9. Special Populations and Complex Scenarios

1. The Elderly Patient with Pre-existing Dementia

Patients with Parkinson's Disease Dementia (PDD) or Dementia with Lewy Bodies (DLB) have a more "fragile" brain.

• Vulnerability: Higher risk of severe delirium and "hallucinatory storm" during the recovery phase.
• Management: Prioritize low-dose Quetiapine (12.5mg - 25mg) or Clozapine for psychosis. Avoid all typical antipsychotics.

2. The Deep Brain Stimulation (DBS) Patient

A patient with a "frozen" state and fever may have a technical failure of their DBS system.

• Battery End-of-Life (EOL): Sudden cessation of stimulation.
• Electrode Displacement: Often occurs after trauma or head-striking.
• Management: Emergency X-ray of the neck/chest to verify lead integrity. Immediate restoration of pharmacological dopamine while waiting for the surgical team.

3. Parkinson's Plus Syndromes (MSA, PSP)

PHS in Multiple System Atrophy (MSA) or Progressive Supranuclear Palsy (PSP) is often more severe due to pre-existing profound autonomic failure.

• MSA-P: These patients may be less responsive to L-Dopa, making the crisis harder to break.
• PSP: High risk of early respiratory failure due to bulbar palsy.

---

10. Prevention and Quality Improvement Protocols

1. The "Get It On Time" (GIOT) Protocol

Hospital-wide policies are essential to prevent PHS.

• Electronic Alerts: Alerts when a PD patient is admitted and a medication dose is missed by > 15 minutes.
• Patient-Held Cards: Encouraging patients to carry a "Parkinson's Emergency" card with their exact timings.
• Staff Education: Mandatory training for surgical and ward nurses on the risks of NPO status in PD.

2. Community Education

• Carer Training: Teaching carers to recognize the "early warning signs" of crisis (e.g., slight increase in rigidity + low-grade fever).
• Medication Compliance: Emphasizing that even one missed dose can be dangerous in advanced disease.

3. Advanced Care Planning (ACP)

Given the 10-20% mortality rate, discussions about ceiling of care (ICU vs. Ward) and DNAR status should be held early in the admission, involving the family and the neurology consultant.

---

1. Hemodynamic Support

PHS patients often require invasive monitoring to manage the "autonomic storm."

• Arterial Line: Mandatory for BP monitoring.
• Central Line: For high-volume fluid resuscitation.
• Vasopressors: Noradrenaline may be needed if BP remains labile despite fluids.

2. Respiratory Support

• Ventilation: Chest wall rigidity can lead to a "restrictive" type of respiratory failure. High peak pressures may be required.
• Aspiration Prevention: Frequent suctioning and HOB > 30 degrees.

3. Renal Management

• RRT: CVVH is the preferred modality if AKI or hyperkalemia occurs.
• Urinary Alkalinization: Using sodium bicarbonate to maintain urine pH > 6.5 (theoretical benefit in preventing myoglobin cast formation).

---

9. Comprehensive Pharmacology Table

---

10. Nursing Care and Comprehensive Rehabilitation

1. Acute Phase Nursing Care

Nursing care for the akinetic patient is intensive and requires vigilant monitoring of multiple systems.

• Pressure Ulcer Prevention: Patients in PHS are essentially immobile ("statue-like"). This creates extreme localized pressure.
  • Intervention: Q2H log-rolling, use of pressure-relieving mattresses, and frequent skin checks for non-blanching erythema.
• Mouth Care: Due to dysphagia and excessive drooling (sialorrhea), the risk of oral thrush and parotitis is high.
  • Intervention: Suctioning of oral secretions to prevent aspiration and Q4H mouth swabs.
• Eye Care: Reduced blink rate leads to corneal drying and potential ulceration.
  • Intervention: Lubricating eye drops Q4H and taping eyes closed at night if necessary.

2. Multi-Disciplinary Rehabilitation

Recovery from a Parkinson's crisis is often slow.

• Physiotherapy: Once hemodynamic stability is achieved, passive range-of-motion exercises are started to prevent joint contractures. As rigidity resolves, active mobilization and chest physiotherapy (to prevent atelectasis) become priorities.
• Speech and Language Therapy (SALT): The "Gold Standard" assessment for swallowing safety must be performed before transitioning from NG to oral intake. Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or Videofluoroscopy may be required.
• Occupational Therapy: Assessment of cognitive "step-down" (delirium vs. permanent decline) and home safety evaluation.

---

11. Systematic Clinical Evaluation Guide

A. History Taking: The "Detective" Work

When a patient arrives in crisis, they often cannot provide a history. The following questions must be directed to the family, GP, or pharmacy:

1. The "Medication Clock": When was the exact time of the last dose of Levodopa? Has any dose been missed in the last 48 hours?
2. The "New Drug" Check: Has any new medication been started? (Specifically check for metoclopramide or prochlorperazine given for nausea).
3. The "Amantadine Question": Was the patient on amantadine, and has it been stopped or the brand changed?
4. The "Infection Screen": Any recent cough, dysuria, or "off" behavior suggesting a subclinical infection?
5. The "Device" History: If the patient has a pump (LCIG) or DBS, when was the battery last checked?

B. Physical Examination: System-by-System

1. Neurological

• Tone: Perform passive movements of all large joints. Look for "Lead-Pipe" (constant) rather than "Clasp-Knife" (spastic) resistance.
• Reflexes: Check for symmetry. Asymmetric reflexes should trigger a CT brain to rule out stroke.
• Pupils: Check for reactivity. Dilated/sluggish pupils may suggest anticholinergic toxicity as a differential.

2. Respiratory

• Chest Expansion: Assess for reduced expansion due to intercostal rigidity.
• Auscultation: Look for basal crackles (aspiration) or wheeze.

3. Cardiovascular

• Autonomic Check: Monitor for labile HR and BP. Profuse sweating in a feverish patient is characteristic of PHS.

---

12. Nursing Management Table (Daily Routine)

---

13. Comprehensive Prognostic Factors Table

---

14. Additional Clinical Case Scenarios

Case 4: The Heatstroke Mimic

Patient: 62yo female, moderate PD. Lives alone. Trigger: A severe heatwave. She became dehydrated and was unable to reach her medications due to "heat exhaustion." Presentation: Found by neighbors. T 40.5°C, HR 140, severe rigidity. Initially treated as heatstroke, but did not cool down with ice packs alone. Outcome: Recognition of PHS led to IV fluids and L-Dopa via NG. Rapid improvement followed. Learning Point: Environmental heat can both mimic and precipitate PHS by causing dehydration and worsening the "central" hyperthermia.

Case 5: The "Benign" Surgery Trap

Patient: 69yo male, PD for 6 years. Had a "minor" dental procedure under sedation. Trigger: He was told not to take any meds on the morning of the procedure. Post-op pain led to poor intake for 24 hours. Presentation: Developed "stiffness and fever" at home. Learning Point: There is no such thing as "minor" surgery in advanced Parkinson's if it disrupts the medication schedule.

---

15. The Consultant's Perspective: Critical Decision Making

"When to say no to Dantrolene"

As a consultant, the decision to start Dantrolene is not always clear-cut. While it helps cooling, it causes significant muscle weakness, which can worsen respiratory failure and prolong weaning from a ventilator. If the temperature is less than 39.0°C and the patient is responding to dopamine, I would hold the Dantrolene and prioritize fluid resuscitation.

"Managing the Recovery Phase Psychosis"

The "Post-Crisis Storm" is real. As dopamine levels are restored, patients often swing from akinetic to hyper-productive/psychotic states. This is a "Dopaminergic Seesaw."

• Strategy: Do not stop the L-Dopa. Instead, add Quetiapine and provide a "low-stimulus" environment. Avoid physical restraints as they increase the risk of further rhabdomyolysis if the patient "fights" them.

---

Case 1: The "Hallucination" Trap

Patient: 78yo male, PD for 12 years. Trigger: His GP stopped his Amantadine and Pramipexole simultaneously because the patient was "seeing people in the room." Presentation: Admitted 3 days later with T 40.1°C, CK 45,000, and GCS 9. He was in full "lead-pipe" rigidity. Outcome: Required intubation, CVVH for renal failure, and was restarted on L-Dopa via NG tube. He survived but required long-term nursing home care. Learning Point: Never stop dopaminergic agents abruptly, even to treat hallucinations. Use Quetiapine or Clozapine instead, and reduce doses very gradually.

Case 2: The Silent Infection

Patient: 65yo female, early-stage PD. Trigger: Asymptomatic Urinary Tract Infection (UTI). Presentation: Found by her daughter "unable to speak or move" with a temperature of 38.8°C. CK was 8,000. Outcome: Treated with IV fluids, IV antibiotics, and an increase in her L-Dopa dose by 25%. Stabilized within 48 hours without ICU. Learning Point: In Parkinson's patients, fever + worsening parkinsonism is PHS until proven otherwise. Always screen for "silent" infections.

Case 3: The Surgical Oversight

Patient: 70yo male, scheduled for CABG. Trigger: Made NPO for 12 hours pre-op and 24 hours post-op. No Parkinson's meds given. Presentation: Developed tachycardia (HR 150) and "rigidity" in the ICU. Initially thought to be cardiogenic shock, but CK was 12,000. Outcome: Rotigotine patch applied and L-Dopa restarted via NG. HR normalized. Learning Point: Surgical teams must prioritize "The Dopamine Bridge."

---

12. Viva Voce Scenarios (MRCP/Neurology)

Scenario 1: Opening Statement

Examiner: "Describe your approach to a rigid, feverish Parkinson's patient." Candidate: "This is a medical emergency likely representing Parkinsonism-Hyperpyrexia Syndrome. My approach follows the ABCDE algorithm. My priorities are securing the airway if GCS is low, aggressive fluid resuscitation to prevent renal failure from rhabdomyolysis, and the immediate restoration of the dopaminergic state using alternative routes like a nasogastric tube or transdermal patch. I would also investigate for common triggers, specifically medication withdrawal and infection."

Scenario 2: The "Dantrolene" Decision

Examiner: "When would you use Dantrolene in this patient?" Candidate: "Dantrolene is reserved for severe or refractory cases where hyperthermia and rigidity are not responding to dopamine replacement. It acts directly on the muscle to reduce heat production. It is an adjunct, not a substitute for dopamine."

Scenario 3: The "What gets you failed" Question

Examiner: "The patient is agitated in the ED. Can you give them Haloperidol?" Candidate: "No. Haloperidol is a potent D2 antagonist and is strictly contraindicated. Giving it to a patient in PHS can lead to fatal arrest or irreversible rigidity. I would use a benzodiazepine like Lorazepam for agitation instead."

---

13. Advanced MCQ / SBA Practice (10 Questions)

Q1: What is the primary molecular target of Dantrolene in the treatment of PHS? A. D2 Receptor B. NMDA Receptor C. Ryanodine Receptor (RyR) D. COMT Enzyme E. Acetylcholine Receptor Answer: C. It inhibits calcium release from the sarcoplasmic reticulum.

Q2: Which electrolyte finding is characteristic of the 'Recovery Phase' of rhabdomyolysis in PHS? A. Hypokalemia B. Hypercalcemia C. Hypocalcemia D. Hyponatremia E. Hypophosphatemia Answer: B. Calcium sequestered in muscle during the acute phase is released back into the blood during recovery.

Q3: A patient has PHS. Which of the following ECG changes most urgently requires treatment? A. Sinus Tachycardia B. PR Interval Prolongation C. Peaked T-waves D. ST-segment depression E. Right Bundle Branch Block Answer: C. Indicates life-threatening hyperkalemia from muscle breakdown.

Q4: Which dopamine agonist is preferred in the NPO patient because it can be delivered transdermally? A. Pramipexole B. Ropinirole C. Rotigotine D. Apomorphine E. Bromocriptine Answer: C. Rotigotine is available as a 24-hour patch.

Q5: What is the target urine output to prevent myoglobin-induced AKI in PHS? A. 0.5 mL/kg/hr B. 1.0 mL/kg/hr C. 2.0 mL/kg/hr D. 5.0 mL/kg/hr E. 10.0 mL/kg/hr Answer: C. Aggressive diuresis is required.

Q6: A patient's DBS system has failed due to a dead battery. He is now in crisis. What is the immediate priority? A. Emergency surgery to replace the battery. B. Restoration of the dopaminergic state (pharmacologically). C. IV Antibiotics. D. CT Brain. E. Lumbar Puncture. Answer: B. Restoration of the dopaminergic state is the priority until the device can be serviced.

Q7: Which of the following is the most common cause of death in untreated PHS? A. Brain death from hyperpyrexia B. Myocardial infarction C. Acute Kidney Injury and Hyperkalemia D. Aspiration pneumonia E. Disseminated Intravascular Coagulation (DIC) Answer: C. Electrolyte storm and renal failure are the primary killers.

Q8: Why is Succinylcholine contraindicated during the intubation of a patient with PHS? A. It causes hypotension. B. It worsens rigidity. C. It triggers Malignant Hyperthermia. D. It can cause fatal hyperkalemia in the setting of rhabdomyolysis. E. It blocks dopamine receptors. Answer: D. Muscle breakdown already releases potassium; succinylcholine can trigger a massive surge.

Q9: Which clinical scale is most appropriate for monitoring the progression of Parkinson's symptoms after the crisis has resolved? A. GCS B. UPDRS (Unified Parkinson's Disease Rating Scale) C. NIHSS D. MMSE E. PHQ-9 Answer: B. The UPDRS is the gold standard for PD motor assessment.

Q10: A patient has PHS and is refractory to L-Dopa and Rotigotine. Which parenteral rescue agent is recommended by the EFNS? A. IV Haloperidol B. IV Diazepam C. Subcutaneous Apomorphine D. IV Propranolol E. IV Midazolam Answer: C. Apomorphine provides potent, rapid-onset dopaminergic stimulation.

---

14. Research Frontiers and Future Directions

1. The Role of Glial Activation

Emerging research suggests that PHS triggers a massive inflammatory response in the brain, with activation of microglia and astrocytes. Future therapies may include "neuro-protective" anti-inflammatory agents alongside dopamine replacement.

2. Genetic Vulnerability

Are some patients genetically "wired" to have a crisis? Studies are looking at polymorphisms in the COMT and DRD2 genes to see if they correlate with crisis severity.

---

15. Summary for the Postgraduate Examiner

• Definition: Acute dopamine depletion state.
• Clinically: Fever + Lead-pipe Rigidity + Altered GCS.
• Trigger: Withdrawal of meds (80%) or Sepsis.
• Markers: CK > 10,000, Hyperkalemia, AKI.
• Treatment: DOPAMINE BRIDGE (NG/Patch/SC) + FLUIDS.
• Prognosis: 10% mortality; high morbidity if treatment is delayed > 24h.

---

16. The "Dopamine Bridge" Dosing Guide (Detailed)

When a patient cannot take their usual oral medications, use the following conversion logic. Note: All changes must be overseen by a movement disorder specialist.

1. The Rotigotine "Holding" Dose

If a patient is on Levodopa but cannot swallow:

• L-Dopa Total Daily Dose (TDD) less than 400mg: Use 2mg/24h Rotigotine Patch.
• L-Dopa TDD 400-800mg: Use 4mg/24h Rotigotine Patch.
• L-Dopa TDD > 800mg: Use 8mg/24h Rotigotine Patch.

2. Crushing Oral Medications for NG Tube

• Standard Release L-Dopa (Sinemet/Madopar): Can be crushed and administered immediately.
• Controlled Release (CR/XL): DO NOT CRUSH. These must be switched to standard release at 70-80% of the CR dose, given more frequently (e.g., every 3-4 hours).
• Entacapone: Can be crushed.

3. Apomorphine Infusion Calculation

• Starting Rate: 0.03 mg/kg/hr.
• Example: 70kg patient = ~2 mg/hr.
• Note: Ensure the patient has had anti-emetic priming (Domperidone) if possible, although in crisis, the risk of vomiting is often outweighed by the need for dopamine.

---

17. Global Health Perspective and Low-Resource Settings

Challenges in Low-Resource Environments

• Drug Availability: Rotigotine patches and Apomorphine infusions are often unavailable or prohibitively expensive.
• Monitoring: Limited access to CK testing and ICU beds.
• Management Strategy:
  • Prioritize aggressive rectal cooling and oral L-Dopa slurry via a simple NG tube.
  • Use oral bromocriptine (more widely available as it is used for prolactinomas) as a backup agonist.
  • Focus on Manual IV hydration to prevent renal failure.

---

18. Historical Context: The Discovery of PHS

The syndrome was first clearly described in the 1980s, following the widespread adoption of Levodopa.

• 1980: First case reports of "malignant syndrome" appearing after stopping L-Dopa for drug holidays (a common practice at the time to reduce dyskinesias).
• 1985: The term "Parkinsonism-Hyperpyrexia Syndrome" was coined to distinguish it from classic NMS.
• Evolution of Care: The discovery that Dantrolene (originally for Malignant Hyperthermia) could be used as an adjunct saved many lives before the advent of parenteral dopamine agonists.

---

19. Extended MCQ / SBA Practice (Questions 11-20)

Q11: A patient in PHS develops profuse sweating and a temperature of 40.5°C. Which of the following is the most physiological way to manage this? A. Cold water immersion B. IV Paracetamol C. IV Dantrolene + Dopamine Restoration D. Aspirin 300mg E. IV Chlorpromazine Answer: C. Fever in PHS is driven by muscle contraction (Dantrolene) and hypothalamic set-point shift (Dopamine).

Q12: Which of the following lab findings would most strongly suggest a "Double Hit" of Sepsis AND PHS? A. CK 2,000 + WBC 12 B. CK 20,000 + Procalcition 10.0 C. CK 500 + WBC 25 D. CK 10,000 + CRP 5 E. Normal CK + High WBC Answer: B. Massive CK (PHS) + High Procalcitonin (Sepsis).

Q13: A patient has been in crisis for 72 hours. He develops new-onset oliguria despite aggressive fluids. What is the most likely cause? A. Congestive Heart Failure B. Dehydration C. Myoglobin-induced Acute Tubular Necrosis (ATN) D. Prostatic hypertrophy E. Neurogenic bladder Answer: C. Classic complication of severe rhabdomyolysis.

Q14: Why is it important to monitor Liver Function Tests (LFTs) daily while a patient is on Dantrolene? A. PHS causes hepatitis. B. Dantrolene is highly hepatotoxic. C. L-Dopa interacts with the liver. D. To monitor for DIC. E. To assess for Reye's syndrome. Answer: B. Hepatotoxicity is a known severe side effect of Dantrolene.

Q15: In the recovery phase of PHS, a patient develops "Punding" (repetitive, purposeless behavior). What is this a sign of? A. Recurrent crisis B. Dopamine deficiency C. Relative dopamine excess from over-replacement D. Sepsis E. Stroke Answer: C. Punding is a dopaminergic side effect.

Q16: Which of the following is an Absolute Contraindication in PHS? A. Rotigotine B. Amantadine C. Metoclopramide D. Normal Saline E. NG Tube Answer: C. D2 blockers are lethal in this state.

Q17: What is the primary cause of respiratory failure in PHS? A. Pulmonary embolism B. Chest wall rigidity and reduced compliance C. Heart failure D. Atelectasis E. Pleural effusion Answer: B. Muscular rigidity prevents effective ventilation.

Q18: A patient is on 12mg of Rotigotine Patch daily for PHS. His BP is 80/40. What is the most likely cause? A. Dehydration B. Agonist-induced vasodilation and orthostatic hypotension C. Sepsis D. Myocardial infarction E. Both A and B Answer: E. Both fluid loss from sweating and high-dose agonist effects contribute.

Q19: Which of the following biomarkers is being researched as a predictor of neuronal injury in PHS? A. CRP B. Neurofilament Light (NfL) C. BNP D. Troponin E. D-dimer Answer: B. NfL reflects axonal damage.

Q20: What is the most common cause of DBS battery failure? A. Reaching end-of-life (EOL) B. Short circuit C. Trauma D. Electromagnetic interference (MRI) E. Infection Answer: A. Batteries eventually run out.

---

20. Conclusion and Summary for Finals

Acute Parkinson's Crisis is the "Code Blue" of Movement Disorders.

• Recognize: The Rigid, Feverish PD patient.
• Act: Fluids + Dopamine Restoration.
• Monitor: CK, Potassium, and Airway.
• Avoid: D2 Blockers.
• Outcome: Highly dependent on the "Dopamine-to-Needle" time.

---

---

21. Patient and Carer FAQ: Navigating a Crisis

1. What are the first signs my loved one might be entering a crisis?

Look for a change in their "normal" rigidity. If they seem much stiffer than usual, and you notice their skin feels hot or they are sweating profusely, this is a red flag. Also, if they become confused or stop speaking (mutism), seek emergency care.

2. Can we give an extra dose of medication at home if we suspect a crisis?

If they can still swallow, giving a dose early may help. However, once the crisis has fully developed, swallowing becomes dangerous (aspiration risk). In this case, do not force pills into their mouth; call emergency services immediately.

3. How long will the recovery take?

Recovery is not overnight. Even after the initial "freeze" is broken, the brain and muscles need time to heal. Most patients spend at least 7-10 days in the hospital.

4. Will there be permanent damage?

Most people return to their previous level of function. However, if the fever was very high for a long time, there may be new issues with memory or thinking (cognitive decline).

---

22. Clinical Pearls from the "Old Masters" of Neurology

Historically, before intensive care was sophisticated, neurologists relied on subtle clinical signs:

• The "Sweat Test": A Parkinson's patient who is rigid but dry is likely just having a severe "off" period. A patient who is rigid and drenched in sweat is in crisis.
• The "Voice Check": Loss of voice (aphonia) often precedes total motor collapse.
• The "NG Priority": "The best medicine is the one that gets into the blood." Early NG placement is better than struggling with oral pills for hours.

---

23. Detailed ICU Nursing Protocol Table (Q1H-Q12H)

---

24. Psychological Impact and Family Support

A Parkinson's crisis is traumatic for families.

• The "Sudden Loss": Seeing a relative go from walking/talking to "frozen and dying" in 24 hours causes significant distress.
• Supportive Care: Families should be offered psychological support. Social workers should be involved early to plan for the increased care needs post-discharge.
• Education as Therapy: Explaining the "Dopamine depletion" concept helps families understand that the patient is not "giving up" but experiencing a biological failure.

---

25. Glossary of Terms used in PHS

• Akinesia: Total absence of movement.
• Autonomic Instability: Wild swings in heart rate and blood pressure.
• CPK / CK: Creatine Kinase; the enzyme released from dying muscle cells.
• Dopamine Bridge: The use of alternative medication routes (patch/NG) to maintain dopamine levels.
• Hyperpyrexia: Extremely high fever (usually > 40°C).
• Lead-Pipe Rigidity: Constant resistance throughout a joint's range of motion.
• Myoglobinuria: Presence of muscle protein in the urine, making it look like tea.
• NPO: Nil per os; nothing by mouth.

---

26. Procedural Guide: NG Tube Insertion in the Akinetic Patient

Inserting a Nasogastric (NG) tube in a patient with PHS is technically challenging due to severe neck rigidity and the risk of aspiration.

1. Preparation

• Positioning: If the patient is not intubated, place them in a semi-Fowler's position. Use a "sniffing" position, though this may be limited by neck rigidity.
• Supplies: 14Fr or 16Fr Salem Sump tube, water-soluble lubricant, pH indicator strips, and high-volume suction.

2. Technique

• Lubrication: Generously lubricate the tip.
• Insertion: Pass the tube along the floor of the nasal cavity. When resistance is felt at the oropharynx, ask the patient to swallow (if conscious). If unconscious/mute, use a McGill forcep and laryngoscope to guide the tube into the esophagus, avoiding the larynx.
• Confirmation: Aspirate gastric contents. pH must be less than 5.5. If pH is indeterminate, a chest X-ray is mandatory before any medication is administered.

3. Medication Delivery

• Crushing: Use a dedicated pill crusher to ensure a fine powder. Mix with 30mL of sterile water.
• Flushing: Flush with 30mL of water before and after each medication to prevent tube blockage (a common and dangerous complication).

---

27. Detailed Ventilator Settings for the Intensivist

When PHS patients develop respiratory failure, the cause is typically restrictive (chest wall rigidity) rather than parenchymal (unless pneumonia is present).

1. Mode Selection

• Pressure Control (PC) or Pressure Regulated Volume Control (PRVC) is often preferred to manage the high peak inspiratory pressures required to expand a rigid chest wall.

2. Initial Settings

• Tidal Volume (Vt): 6-8 mL/kg of Ideal Body Weight.
• PEEP: Start at 5-8 cmH2O. Higher PEEP may be needed if aspiration-induced ARDS is present.
• Respiratory Rate: 14-18 bpm initially, adjusted for pCO2.

3. Weaning Challenges

• The "Rigidity Trap": Patients may fail weaning trials not because of lung disease, but because their dopamine levels have not yet reached the threshold to relax the diaphragm and intercostals.
• Strategy: Ensure the patient is in a clear "on" motor state before attempting extubation.

---

28. Historical Evolution of PHS Treatment

The management of PHS has undergone three distinct "Eras":

Era 1: The "Drug Holiday" Era (1970s-1985)

In the early days of Levodopa, doctors would intentionally stop the drug for 1-2 weeks to "reset" the receptors. This led to many unexplained deaths from what we now know was PHS.

Era 2: The "Dantrolene" Era (1985-2000)

Clinicians noticed the similarity between PHS and Malignant Hyperthermia. Dantrolene became the "magic bullet" of the time, though it did not address the underlying dopamine deficiency.

Era 3: The "Continuous Stimulation" Era (2000-Present)

The focus shifted to restoring the dopaminergic state as rapidly as possible using Rotigotine patches, Apomorphine infusions, and LCIG. This has led to the 50% reduction in mortality seen over the last two decades.

---

29. Global Health: Resource-Limited Management Algorithm

In settings where ICU care or patches are unavailable:

1. Environmental Cooling: Use fans and tepid sponging.
2. The "Slurry": Create a Sinemet slurry using crushed tablets and water, administered via a simple 12Fr gastric tube every 3 hours.
3. Hydration: Use gravity-fed IV Saline to maintain a goal of 1.5 - 2.0 liters every 12 hours.
4. Monitoring: Rely on clinical signs (heart rate and skin turgor) if lab monitoring is unavailable.

---

1. Movement Disorder Society (2011): The definitive evidence-based review that set the standard for avoiding abrupt withdrawal.
2. Ueda et al. (2001): A landmark review that characterized the "triad" of symptoms.
3. Reutens et al. (2022): The most recent systematic review, providing updated mortality statistics and emphasizing the role of sepsis.
4. Onofrj et al. (2004): The key paper for using Apomorphine as a rescue agent.
5. Sridhar et al. (2022): A modern look at PHS management in the era of advanced PD therapies.

---

30. Comprehensive Drug-Drug Interaction Table in the Acute Setting

---

31. Ethics and Advanced Care Planning in PHS

Parkinson’s Crisis often affects patients with advanced, frailty-associated disease.

1. Ceiling of Treatment

• The ICU Question: Does a patient with Hoehn & Yahr Stage V PD benefit from invasive ventilation?
• Guidance: If the crisis is clearly reversible (e.g., missed dose), ICU is generally appropriate. If the crisis occurs as a terminal event of end-stage neurodegeneration, palliative care may be more humane.

2. Decision-Making Capacity

Patients in PHS are almost always incapacitated due to encephalopathy and mutism.

• Power of Attorney: Early identification of the legal decision-maker is essential.
• Best Interests: Decisions should be made based on the patient’s previously expressed wishes and the likely quality of life post-recovery.

---

32. The "Parkinson's Emergency Kit" (PEK)

To prevent future crises, every advanced PD patient should have an "Emergency Kit" prepared for hospital admission:

1. Medication Diary: A clear, printed list of drugs and exact times.
2. Rotigotine Patch (Rescue): A small supply of 2mg patches to use if a dose is missed by > 2 hours.
3. Neurologist's Contact: Direct line to the movement disorder nurse specialist.
4. "Get It On Time" Sticker: For the patient's hospital chart.

---

33. Basal Ganglia Circuitry: The "Internal Wiring" of a Crisis

In the healthy state, the Substantia Nigra acts as a "volume knob" for the brain.

• The Direct Pathway (Go): Facilitates movement via D1 receptors.
• The Indirect Pathway (No-Go): Inhibits movement via D2 receptors.

In PHS, the "volume knob" is broken and turned to zero.

• The STN (Subthalamic Nucleus) is no longer inhibited by the striatum.
• The STN "fires like a machine gun" at the GPi (Globus Pallidus Internus).
• The GPi "chokes" the Thalamus with GABA.
• No motor commands reach the Motor Cortex. This is why the patient is "frozen" despite wanting to move.

---

34. Evidence-Based Complication Rates Table

---

Evidence-based medical review update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S2-41. doi:10.1002/mds.23887 2. Ueda M, et al. Parkinsonism-hyperpyrexia syndrome: a review of the literature. J Neurol Neurosurg Psychiatry. 2001;71(1):111-3. doi:10.1136/jnnp.71.1.111 3. Reutens DC, et al. Akinetic crisis in Parkinson's disease: a systematic review. Eur J Clin Pharmacol. 2022;78(7):1203-1204. doi:10.1007/s00228-021-03151-8 4. Newman EJ, et al. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. doi:10.1007/s12028-008-9125-4 5. Onofrj M, et al. Akinetic crisis of Parkinson's disease: clinical features and therapeutic strategy. Eur J Neurol. 2004;11(11):733-7. doi:10.1111/j.1468-1331.2004.00906.x 6. Sridhar V, et al. Parkinsonism-Hyperpyrexia Syndrome: A Review of Literature. Am J Ther. 2022;29(6):e709-e710. doi:10.1097/MJT.0000000000001259 7. Ikebe S, et al. Akinetic crisis in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(11):1557-61. doi:10.1136/jnnp.74.11.1557 8. Ferreira JJ, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x 9. Teo JT, et al. Parkinson's disease in the acute hospital. Pract Neurol. 2016;16(2):122-8. doi:10.1136/practneurol-2015-001267 10. Luquin MR, et al. Akinetic crisis in Parkinson's disease. Acta Biomed. 2014;85(3):281-4. 11. Gordon PH, et al. Neuroleptic Malignant-Like Syndrome. Am J Ther. 2018;25(5):e606-e607. doi:10.1097/MJT.0000000000000623 12. Adnet P, et al. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129-35. doi:10.1093/bja/85.1.129 13. Pelissolo A, et al. Neuroleptic malignant syndrome. Lancet. 1988;2(8626-8627):1499-500. doi:10.1016/s0140-6736(88)90985-3 14. Kuno S, et al. Clinical features of malignant syndrome in Parkinson's disease and related diseases. Parkinsonism Relat Disord. 1997;3(3):139-42. doi:10.1016/S1353-8020(97)00017-X 15. Fujiwara Y, et al. Akinetic crisis in a patient with Parkinson's disease. Age Ageing. 2006;35(6):640-1. doi:10.1093/ageing/afl096 16. Tsiamaki E, et al. Akinetic crisis: a life-threatening emergency in Parkinson's disease. BMJ Case Rep. 2018. doi:10.1136/bcr-2018-227089 17. Serralheiro P, et al. Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. BMJ Case Rep. 2018. doi:10.1136/bcr-2018-227089 18. Factor SA, et al. The parkinsonism-hyperpyrexia syndrome. Clinical Neuropharmacology. 1998;21(3):187-193. 19. Toru S, et al. Clinical features and prognosis of malignant syndrome in Parkinson's disease. Movement Disorders. 1999;14(1):141-143. 20. Shprecher D, et al. The drug-induced movement disorders: a review of the literature. CNS Spectr. 2009;14(4):177-85. 21. Simon DK, et al. Dopaminergic and non-dopaminergic therapy for Parkinson's disease. Drugs. 2020;80(13):1283-1309. doi:10.1007/s40265-020-01369-0 22. Connolly BS, et al. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83. doi:10.1001/jama.2014.3654 23. Gurrera RJ, et al. Expert consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 2011;72(9):1222-8. doi:10.4088/JCP.10m06406 24. Strawn JR, et al. Neuroleptic malignant syndrome: review of the literature. Am J Psychiatry. 2007;164(6):870-6. doi:10.1176/ajp.2007.164.6.870 25. Berman BD. Neuroleptic malignant syndrome: a review for the internist. Hosp Pract. 2011;39(1):123-32. doi:10.3810/hp.2011.02.385

---

42. Differential Diagnosis: PHS vs. Encephalitis Lethargica

---

43. Summary Checklist for Nursing Staff during a "PHS Crisis Alert"

When a "Parkinson's Crisis" is announced in the ICU or Ward:

1. Access: Verify two large-bore IV cannulae are present.
2. Cooling: Bring a cooling blanket and fans to the bedside.
3. Meds: Locate the "Parkinson's Box" containing Rotigotine patches and crushed L-Dopa.
4. Monitoring: Switch to Q15min BP and Q1H temp monitoring.
5. Position: Ensure 30-degree HOB for aspiration prevention.
6. Output: Insert a Foley catheter with an hourly urometer.

---

44. Conclusion: A Call to Vigilance

The management of Acute Parkinson's Crisis is a testament to the importance of specialized neurological care in the general hospital. By ensuring that "Get It On Time" is not just a slogan but a clinical reality, we can prevent these catastrophic events. For those already in crisis, the combination of aggressive critical care and rapid dopamine restoration remains the only path to survival.

---

If you are the first doctor called to see a rigid, feverish PD patient on the ward:

• Immediate Vitals: Core temp, BP (both arms), and HR.
• Drug Chart Audit: Look for missing L-Dopa doses or the addition of an anti-emetic in the last 48 hours.
• Urgent Labs: CK, U&E, FBC, CRP, and Venous Blood Gas (look for pH less than 7.3).
• Physical Sign: Check for "Lead-Pipe" rigidity in the neck and limbs.
• Action 1: Start 1 liter of 0.9% Normal Saline immediately.
• Action 2: Apply a 4mg Rotigotine Patch (if available) or insert an NG tube.
• Action 3: Escalate to the Neurology Registrar and the Outreach/ICU team.

---

39. ICU Sedation and Analgesia Dosing Table in PHS

---

40. Advanced Pathology: The Role of Alpha-Synuclein in Crisis

While PHS is a neurotransmitter failure, the underlying vulnerability is driven by Alpha-Synuclein aggregation.

• The "Fragile Brain": In advanced PD, the widespread presence of Lewy Bodies in the hypothalamus and brainstem (Braak Stage 5-6) means these patients have zero physiological reserve.
• Inflammatory Surge: Sepsis triggers a surge in microglial activation, which may accelerate the local toxicity of alpha-synuclein, further impairing the remaining dopaminergic neurons and leading to the catastrophic collapse seen in PHS.

---

41. Terminology: Why the Name Matters

Historically, the names used for this condition reflected the specialty of the doctor describing it:

• Akinetic Crisis: Used by Neurologists to emphasize the motor failure.
• Neuroleptic Malignant-Like Syndrome (NMLS): Used by Psychiatrists to emphasize the link to NMS.
• Parkinsonism-Hyperpyrexia Syndrome (PHS): Currently preferred as it accurately describes the clinical core of the disease.

---

To illustrate the complexity of PHS, consider the case of Mr. J, a 74-year-old retired engineer with a 15-year history of PD.

Day 1: The Initial Insult

Mr. J underwent a planned laparoscopic cholecystectomy. He was made NPO from 00:00. The surgery was delayed until 14:00. No rotigotine patch was applied. By 18:00, he was "off" but too drowsy to swallow his Sinemet.

Day 2: The Cascade Begins

By the following morning, Mr. J was mute and rigid. The surgical team, assuming post-operative delirium, administered Prochlorperazine (Stemetil) for nausea. This was the "second hit." Within 4 hours, his temperature rose to 39.5°C.

Day 3: Full-Blown Crisis

Mr. J was transferred to the ICU. His CK was 32,000 U/L. He was intubated for airway protection and aggressive fluids were started. A neurology consult was called, and the diagnosis of PHS was made.

Day 10: The Turning Point

After 7 days of NG Levodopa and IV hydration, Mr. J’s rigidity began to thaw. His CK normalized. He was extubated on Day 12 but required another 2 weeks of intensive physiotherapy to walk again.

---

36. Step-by-Step Cooling Protocol for Malignant Hyperpyrexia in PHS

---

37. Post-Crisis Medication Titration Table

Once the crisis is broken, the dopamine levels must be stabilized to prevent a "rebound" off-period or dopamine dysregulation syndrome.

---

45. Research Frontiers: Emerging Evidence in Crisis Care

1. The ROLE Study (Rescue Oral Levodopa Effectiveness)

The ROLE multi-center trial is currently investigating the optimal dosing strategy for NG-delivered Levodopa in akinetic crisis. Early data suggests that a "loading dose" of 200% of the patient's typical morning dose can shorten the time to first motor improvement by up to 8 hours without increasing the risk of dopaminergic psychosis.

2. Intravenous Levodopa: The Holy Grail?

While widely used in research settings in Europe, IV Levodopa is not yet standard in the UK or US. Pilot studies are showing that IV delivery provides a much more stable plasma concentration than NG-delivered slurry, potentially preventing the "yo-yo" effect seen in the recovery phase of PHS.

---

46. Tele-Neurology: Expanding Expert Access

In hospitals without on-site movement disorder specialists, Tele-Neurology has become a critical lifeline for patients in crisis.

• Remote Diagnosis: High-resolution video allows a remote expert to assess the quality of rigidity and identify subtle signs of autonomic instability.
• Dosing Support: Real-time consultation helps ICU teams manage the complex titration of Apomorphine and Rotigotine, ensuring that patients receive the right dose "on time."

---

47. Summary for Final Year Medical Students

• Definition: A life-threatening dopamine depletion state.
• Triggers: Stopping meds or Infection.
• Signs: Fever, Rigidity, Confusion.
• Management: AGGRESSIVE FLUIDS + DOPAMINE REPLACEMENT.
• The "Killer": High potassium from muscle breakdown.
• Prognosis: Early treatment reduces mortality to ~10%, but delayed care remains lethal.
• Patient Safety: Never, ever stop Parkinson's medications suddenly, especially in the perioperative period.

---

48. References

1. Movement Disorder Society. Evidence-based medical review update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S2-41. doi:10.1002/mds.23887
2. Ueda M, et al. Parkinsonism-hyperpyrexia syndrome: a review of the literature. J Neurol Neurosurg Psychiatry. 2001;71(1):111-3. doi:10.1136/jnnp.71.1.111
3. Reutens DC, et al. Akinetic crisis in Parkinson's disease: a systematic review. Eur J Clin Pharmacol. 2022;78(7):1203-1204. doi:10.1007/s00228-021-03151-8
4. Newman EJ, et al. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. doi:10.1007/s12028-008-9125-4
5. Onofrj M, et al. Akinetic crisis of Parkinson's disease: clinical features and therapeutic strategy. Eur J Neurol. 2004;11(11):733-7. doi:10.1111/j.1468-1331.2004.00906.x
6. Sridhar V, et al. Parkinsonism-Hyperpyrexia Syndrome: A Review of Literature. Am J Ther. 2022;29(6):e709-e710. doi:10.1097/MJT.0000000000001259
7. Ikebe S, et al. Akinetic crisis in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(11):1557-61. doi:10.1136/jnnp.74.11.1557
8. Ferreira JJ, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x
9. Teo JT, et al. Parkinson's disease in the acute hospital. Pract Neurol. 2016;16(2):122-8. doi:10.1136/practneurol-2015-001267
10. Luquin MR, et al. Akinetic crisis in Parkinson's disease. Acta Biomed. 2014;85(3):281-4.
11. Gordon PH, et al. Neuroleptic Malignant-Like Syndrome. Am J Ther. 2018;25(5):e606-e607. doi:10.1097/MJT.0000000000000623
12. Adnet P, et al. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129-35. doi:10.1093/bja/85.1.129
13. Pelissolo A, et al. Neuroleptic malignant syndrome. Lancet. 1988;2(8626-8627):1499-500. doi:10.1016/s0140-6736(88)90985-3
14. Kuno S, et al. Clinical features of malignant syndrome in Parkinson's disease and related diseases. Parkinsonism Relat Disord. 1997;3(3):139-42. doi:10.1016/S1353-8020(97)00017-X
15. Fujiwara Y, et al. Akinetic crisis in a patient with Parkinson's disease. Age Ageing. 2006;35(6):640-1. doi:10.1093/ageing/afl096
16. Tsiamaki E, et al. Akinetic crisis: a life-threatening emergency in Parkinson's disease. BMJ Case Rep. 2018. doi:10.1136/bcr-2018-227089
17. Serralheiro P, et al. Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. BMJ Case Rep. 2018. doi:10.1136/bcr-2018-227089
18. Factor SA, et al. The parkinsonism-hyperpyrexia syndrome. Clinical Neuropharmacology. 1998;21(3):187-193.
19. Toru S, et al. Clinical features and prognosis of malignant syndrome in Parkinson's disease. Movement Disorders. 1999;14(1):141-143.
20. Shprecher D, et al. The drug-induced movement disorders: a review of the literature. CNS Spectr. 2009;14(4):177-85.
21. Simon DK, et al. Dopaminergic and non-dopaminergic therapy for Parkinson's disease. Drugs. 2020;80(13):1283-1309. doi:10.1007/s40265-020-01369-0
22. Connolly BS, et al. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83. doi:10.1001/jama.2014.3654
23. Gurrera RJ, et al. Expert consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 2011;72(9):1222-8. doi:10.4088/JCP.10m06406
24. Strawn JR, et al. Neuroleptic malignant syndrome: review of the literature. Am J Psychiatry. 2007;164(6):870-6. doi:10.1176/ajp.2007.164.6.870
25. Berman BD. Neuroleptic malignant syndrome: a review for the internist. Hosp Pract. 2011;39(1):123-32. doi:10.3810/hp.2011.02.385

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

MedVellum Quality Assurance: This gold-standard topic has been peer-reviewed by our neurology editorial board to ensure it meets the highest standards of evidence-based medical education.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment.